04Jun 2016
Springer

Osteoporos Int. 2016 Jun;27(6):1953-66. doi: 10.1007/s00198-015-3468-4. Epub 2016 Jan 18.

Hip, whole body and femoral neck BMD were reduced to a statistically significant level in AN but not BN groups. The meta-regression was limited by the number of included studies and did not find any significant predictors. This meta-analysis confirms the association between low BMD and AN and presents a strong argument for assessing BMD not only in patients with AN, but also in patients with BN.

Autor: Robinson L, Aldridge V, Clark EM, Misra M, Micali N.
04Jun 2016
NEJM

N Engl J Med. 2016 Jun 30;374(26):2553-62. doi: 10.1056/NEJMoa1509342.

CONCLUSIONS: Our study showed that Pyle’s disease was caused by a deficiency of sFRP4, that cortical-bone and trabecular-bone homeostasis were governed by different mechanisms, and that sFRP4-mediated cross-regulation between Wnt and BMP signaling was critical for achieving proper cortical-bone thickness and stability.

Autor: Simsek Kiper PO,Saito H,Gori F,Unger S,Hesse E,Yamana K,Kiviranta R,Solban N,Liu J,Brommage R,Boduroglu K,Bonafé L,Campos-X. B,Dikoglu E,Eastell R,Gossiel F,Harshman K,Nishimura G,Girisha KM,Stevenson BJ, akita H,Rivolta C,Superti-Furga A,Baron R
04Jun 2016
endocrine society

J Clin Endocrinol Metab. 2016 Jun;101(6):2273-83. doi: 10.1210/jc.2015-3907. Epub 2016 Mar 4.

CONCLUSIONS: This document not only provides a summary of our current knowledge but also places recent advances in its management into a context that should enhance future advances in our understanding of hypoparathyroidism.

Autor: Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT Jr.
04May 2016
MPubmed

J Clin Endocrinol Metab. 2016 May;101(5):2226-34. doi: 10.1210/jc.2016-1104. Epub 2016 Mar 23.

Previously reported racial differences in DBP concentration are likely from monoclonal assay bias, as there was no racial difference in DBP concentration by other methods. This confirms the poor vitamin D status of many African-Americans and the utility of total 25OHD in assessing vitamin D in the general population.

Autor: Nielson CM,Jones KS,Chun RF,Jacobs JM,Wang Y,Hewison M,Adams JS,Swanson CM,Lee C,anderschueren D,Pauwels S,Prentice A,Smith RD,Shi T,Gao Y,Schepmoes AA,Zmuda JM,Lapidus J,Cauley JA,Bouillon R,Schoenmakers I,Orwoll ES;OFMen (MrOS) Research G.
04May 2016
MPubmed

Osteoporos Int. 2016 May;27(5):1677-82. doi: 10.1007/s00198-016-3553-3. Epub 2016 Mar 1

Patients should be encouraged to continue denosumab therapy long term. If discontinuation does occur, appropriate steps must be taken to prevent the rapid bone loss and probable acute fracture risk.

Autor: Loi F, Córdova LA, Pajarinen J, Lin TH, Yao Z, Goodman SB.
04Abr 2016
endocrine society

J Clin Endocrinol Metab. 2016 Apr;101(4):1414-21. doi: 10.1210/jc.2015-4017. Epub 2016 Feb 10.

In this large, prospective, observational cohort study of postmenopausal women in the WHI, Cox proportional hazard regression models showed that sodium intake at or near recommended levels is not likely to impact bone metabolism.

Autor: Carbone L, Johnson KC, Huang Y, Pettinger M, Thomas F, Cauley J, Crandall C, Tinker L, LeBoff MS, Wactawski-Wende J, Bethel M, Li W, Prentice R.
04Abr 2016
endocrine society

J Clin Endocrinol Metab. 2016 Apr;101(4):1353-63. doi: 10.1210/jc.2015-4181. Epub 2016 Feb 9.

We compared effects of teriparatide and denosumab on PTH, bone turnover markers, and bone histomorphometry in osteoporotic postmenopausal women. The findings were inconsistent with an early indirect anabolic effect of denosumab.

Autor: Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA
04Abr 2016
Springer

Osteoporos Int. 2016 Apr;27(4):1425-40. doi: 10.1007/s00198-015-3367-8. Epub 2015 Oct 16. Review

Supplementation with calcium and vitamin D is often necessary in the SOT population due to a high incidence of vitamin D deficiency. Bisphosphonate therapy is most commonly used for prevention and treatment of osteoporosis, but therapy can be limited by renal dysfunction which is common in transplant recipients. Alternative agents such as teriparatide and calcitonin have not been shown to provide a significant impact on the rate of fractures in this population. Additionally, denosumab may be a promising treatment option due to its novel mechanism of action, and is currently being studied in renal transplant patients. Timely initiation of supplementation and treatment, and minimizing glucocorticoid exposure prior to and after transplantation will aid in the prevention and proper management of osteoporosis in these patients.

Autor: Early C, Stuckey L, Tischer S.
04Abr 2016
Springer

Osteoporos Int. 2016 Apr;27(4):1281-386. doi: 10.1007/s00198-015-3440-3. Epub 2016 Feb 8

The best evidence (grade A) is available for positive effects of calcium intake and physical activity, especially during the late childhood and peripubertal years-a critical period for bone accretion. Good evidence is also available for a role of vitamin D and dairy consumption and a detriment of DMPA injections. However, more rigorous trial data on many other lifestyle choices are needed and this need is outlined in our research agenda. Implementation strategies for lifestyle modifications to promote development of peak bone mass and strength within one’s genetic potential require a multisectored (i.e., family, schools, healthcare systems) approach.

Autor: Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, O’Karma M, Wallace TC, Zemel BS